Naloxone manufacturers could receive another regulatory nudge from the US Food and Drug Administration to produce an OTC nasal spray of the opioid overdose medication.
Commissioner Robert Califf said the agency is having “serious discussions right now about what we can do to exert some changes compared to the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?